Muscle Invasive Urothelial Carcinoma
Advertisement
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
The AMBASSADOR study demonstrated a significant improvement in disease-free survival for pembrolizumab.
Dr. Plimack provides an update on the SWOG S1314 trial for MIBC, including four genes predictive of pT0 disease after NAC.
Immunotherapy is often used for metastatic disease, yet it is still under investigation in neoadjuvant and adjuvant settings.
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
In patients with MIBC, any tumors with ATM, RB1, FANCC, or ERCC2 mutations were likely to respond to treatment with NAC.
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
The new recommendations included changes to neoadjuvant and adjuvant chemotherapy and radical cystectomy.
Results from the NIAGARA trial show significant survival benefits with durvalumab for muscle invasive bladder cancer.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC.
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Of the 26 patients with pathological assessment upon safety visit, all reached pCR, while none received cystectomy.
Neoadjuvant SG shows promising clinical activity in patients with MIBC and may help avoid radical cystectomy.
Disitamab vedotin, a novel anti-HER2 antibody-drug conjugate, was paired with toripalimab, an anti–PD-1 monoclonal ...
For patients with organ-confined urothelial carcinoma of urinary bladder, trimodal therapy is recommended.
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
Identifying tumor biomarkers associated with pCR to neoadjuvant pembro or NAC prior to cystectomy in patients with MIBC.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.